ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Bone marrow infiltration,Haematological disorders,Haematological disorders NEC,Blood,N
1,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
1,3,Plasma cell myeloma,Plasma cell myelomas,Plasma cell neoplasms,Neopl,Y
1,4,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1,5,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2,1,Plasma cell myeloma,Plasma cell myelomas,Plasma cell neoplasms,Neopl,N
2,2,Plasma cell myeloma recurrent,Plasma cell myelomas,Plasma cell neoplasms,Neopl,N
2,3,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4,1,Bone marrow failure,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
4,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4,3,Paraproteinaemia,Plasma cell neoplasms NEC,Plasma cell neoplasms,Neopl,N
4,4,Plasma cell myeloma,Plasma cell myelomas,Plasma cell neoplasms,Neopl,N
5,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
5,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
5,3,Plasma cell myeloma refractory,Plasma cell myelomas,Plasma cell neoplasms,Neopl,N
5,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
6,1,Disease recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
6,2,Volvulus,Gastrointestinal stenosis and obstruction NEC,Gastrointestinal stenosis and obstruction,Gastr,Y
7,1,Autoimmune haemolytic anaemia,Anaemias haemolytic immune,Haemolyses and related conditions,Blood,N
7,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
7,3,Haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
7,4,Haemolytic anaemia,Anaemias haemolytic NEC,Haemolyses and related conditions,Blood,N
7,5,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
8,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
9,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
10,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
10,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
10,3,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
10,4,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
11,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
11,2,Plasma cell myeloma,Plasma cell myelomas,Plasma cell neoplasms,Neopl,Y
12,1,Cerebral infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
12,2,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
13,1,Peripheral sensory neuropathy,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
13,2,Sensory loss,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
14,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
14,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
14,3,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,Y
15,1,Plasma cell myeloma,Plasma cell myelomas,Plasma cell neoplasms,Neopl,N
16,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
16,2,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
17,1,Plasma cell myeloma,Plasma cell myelomas,Plasma cell neoplasms,Neopl,Y
18,1,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
19,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
19,2,Tuberculosis,Tuberculous infections,Mycobacterial infectious disorders,Infec,N
20,1,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
21,1,Laboratory test interference,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
22,1,Plasma cell myeloma,Plasma cell myelomas,Plasma cell neoplasms,Neopl,Y
23,1,Plasma cell myeloma recurrent,Plasma cell myelomas,Plasma cell neoplasms,Neopl,Y
24,1,Plasma cell myeloma,Plasma cell myelomas,Plasma cell neoplasms,Neopl,Y
25,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,Y
26,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
27,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
27,2,Skin toxicity,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
27,3,Stevens-Johnson syndrome,Bullous conditions,Epidermal and dermal conditions,Skin,N
28,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
28,2,Lung disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
29,1,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
29,2,Hospice care,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
29,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
29,4,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
29,5,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
29,6,Plasma cell myeloma,Plasma cell myelomas,Plasma cell neoplasms,Neopl,N
30,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
30,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
30,3,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
30,4,Pneumocystis jirovecii pneumonia,Pneumocystis infections,Fungal infectious disorders,Infec,N
30,5,Pneumonia klebsiella,Klebsiella infections,Bacterial infectious disorders,Infec,N
30,6,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
30,7,Rhinitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
30,8,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
31,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
31,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
31,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,Y
32,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
33,1,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
34,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
34,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
35,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
35,2,Laboratory test interference,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
36,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,Y
37,1,Myelodysplastic syndrome,Myelodysplastic syndromes,Leukaemias,Neopl,N
38,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
39,1,Haematotoxicity,Haematological disorders,Haematological disorders NEC,Blood,N
40,1,Haematotoxicity,Haematological disorders,Haematological disorders NEC,Blood,N
41,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
42,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
42,2,Infusion related reaction,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
42,3,Lymphocyte count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
42,4,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
42,5,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
43,1,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
43,2,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
44,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
45,1,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
45,2,Neoplasm recurrence,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
45,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
46,1,Acute hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,Y
46,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
47,1,Liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,Y
48,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
48,2,Atrial flutter,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
49,1,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
49,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
49,3,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
49,4,Poor quality product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
49,5,Productive cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
49,6,Upper respiratory tract infection,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
50,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
51,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,Y
